Protective Effects of Brain Infarction by <i>N</i> -Acetylcysteine Derivatives

  • Takeshi Uemura
    From the Amine Pharma Research Institute, Innovation Plaza at Chiba University, Japan (T.U., K.I.)
  • Kenta Watanabe
    Department of Clinical and Analytical Biochemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Japan (K.W., K.K., K.H., N.K., M.K., H.T., T.T., K.I.)
  • Kenta Ko
    Department of Clinical and Analytical Biochemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Japan (K.W., K.K., K.H., N.K., M.K., H.T., T.T., K.I.)
  • Kyohei Higashi
    Department of Clinical and Analytical Biochemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Japan (K.W., K.K., K.H., N.K., M.K., H.T., T.T., K.I.)
  • Noriyuki Kogure
    Department of Clinical and Analytical Biochemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Japan (K.W., K.K., K.H., N.K., M.K., H.T., T.T., K.I.)
  • Mariko Kitajima
    Department of Clinical and Analytical Biochemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Japan (K.W., K.K., K.H., N.K., M.K., H.T., T.T., K.I.)
  • Hiromitsu Takayama
    Department of Clinical and Analytical Biochemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Japan (K.W., K.K., K.H., N.K., M.K., H.T., T.T., K.I.)
  • Koichi Takao
    Laboratory of Bioorganic Chemistry, Department of Pharmaceutical Technology, Josai University, Saitama, Japan (K.T., Y.S.)
  • Yoshiaki Sugita
    Laboratory of Bioorganic Chemistry, Department of Pharmaceutical Technology, Josai University, Saitama, Japan (K.T., Y.S.)
  • Akihiko Sakamoto
    Department of Clinical Biochemistry, Chiba Institute of Science, Japan (A.S., Y.T., K.K.).
  • Yusuke Terui
    Department of Clinical Biochemistry, Chiba Institute of Science, Japan (A.S., Y.T., K.K.).
  • Toshihiko Toida
    Department of Clinical and Analytical Biochemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Japan (K.W., K.K., K.H., N.K., M.K., H.T., T.T., K.I.)
  • Keiko Kashiwagi
    Department of Clinical Biochemistry, Chiba Institute of Science, Japan (A.S., Y.T., K.K.).
  • Kazuei Igarashi
    From the Amine Pharma Research Institute, Innovation Plaza at Chiba University, Japan (T.U., K.I.)

この論文をさがす

説明

<jats:sec> <jats:title>Background and Purpose—</jats:title> <jats:p> We recently found that acrolein (CH <jats:sub>2</jats:sub> =CH-CHO) is more strongly involved in brain infarction compared with reactive oxygen species. In this study, we looked for acrolein scavengers with less side effects. </jats:p> </jats:sec> <jats:sec> <jats:title>Methods—</jats:title> <jats:p> Photochemically induced thrombosis model mice were prepared by injection of Rose Bengal. Effects of <jats:italic>N</jats:italic> -acetylcysteine (NAC) derivatives on brain infarction were evaluated using the public domain National Institutes of Health image program. </jats:p> </jats:sec> <jats:sec> <jats:title>Results—</jats:title> <jats:p> NAC, NAC ethyl ester, and NAC benzyl ester (150 mg/kg) were administered intraperitoneally at the time of induction of ischemia, or these NAC derivatives (50 mg/kg) were administered 3× at 24-h intervals before induction of ischemia and 1 more administration at the time of induction of ischemia. The size of brain infarction decreased in the order NAC benzyl ester>NAC ethyl ester>NAC in both experimental conditions. Detoxification of acrolein occurred through conjugation of acrolein with glutathione, which was catalyzed by glutathione <jats:italic>S</jats:italic> -transferases, rather than direct conjugation between acrolein and NAC derivatives. The level of glutathione <jats:italic>S</jats:italic> -transferases at the locus of brain infarction was in the order of administration of NAC benzyl ester>NAC ethyl ester>NAC>no NAC derivatives, suggesting that NAC derivatives stabilize glutathione <jats:italic>S</jats:italic> -transferases. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p> The results indicate that detoxification of acrolein by NAC derivatives is caused through glutathione conjugation with acrolein catalyzed by glutathione <jats:italic>S</jats:italic> -transferases, which can be stabilized by NAC derivatives. This is a new concept of acrolein detoxification by NAC derivatives. </jats:p> </jats:sec>

収録刊行物

  • Stroke

    Stroke 49 (7), 1727-1733, 2018-07

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (4)*注記

もっと見る

参考文献 (26)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ